Vincenzo Di Marzo to lead GW’s pre-clinical research

Leading cannabinoid scientist joins cannabis medicine specialist

Professor Vincenzo Di Marzo has agreed to direct GW Pharmaceuticals’ global pre-clinical research programme and has become research director of GW Research Ltd and GW’s Cannabinoid Research Institute at Porton Down in the UK.

Professor Di Marzo is a leading cannabinoid scientist, co-author of more than 460 peer-reviewed publications, and in 2010 was recognised as Thompson Reuters 'top scientist of the decade' for pharmacology and toxicology.

He has previously served as president of the International Cannabinoid Research Society (ICRS) and is a recipient of ICRS’s Mechoulam Award for ‘outstanding contributions to cannabinoid research’.

Professor Di Marzo is a research director at the Institute of Biomolecular Chemistry of the National Research Council (ICB-CNR) in Pozzuoli, Naples, Italy, coordinator of the Endocannabinoid Research Group in the Naples region, and an adjunct associate professor in the Department of Pharmacology and Toxicology at the Medical College of Virginia at Virginia Commonwealth University in Richmond.

In his new engagement with GW Pharmaceuticals, Professor Di Marzo will be responsible for coordinating the research efforts of GW’s global network of cannabinoid scientists. This network now extends to more than 25 academic institutions in 11 countries and involves research in a wide range of therapeutic areas, including oncology, neuroscience, metabolic disease, inflammatory disease, gastroenterology, and dermatology. The objective of this research effort is to progress a number of GW’s new cannabinoid pipeline candidates to full clinical development.

You may also like

Manufacturing

Momentum in the US cannabidiol market gains retailers' attention

Walmart and other big-name stores in talks with food and drinks makers in preparation for the day CBD-enriched products are allowed on the shelves
Ingredients

World's first prescription cannabis medicine launched in the UK

UK is the first country to grant a full regulatory authorisation for Sativex, which will be marketed to treat spasticity associated with Multiple Sclerosis
Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
Manufacturing

Clariant opens first US pharmaceutical-grade PEG excipient manufacturing site in Texas

Clariant has expanded its Clear Lake facility in Texas to produce GMP-compliant pharmaceutical-grade polyethylene glycol excipients, marking its first US-based manufacturing site for the products and strengthening supply chain resilience for North American and Latin American pharma customers
Ingredients

Sequential extraction kit enables multiomics analysis from a single sample

Thermo Fisher Scientific launches a magnetic bead-based workflow to support genomic, transcriptomic and proteomic research
Ingredients

Echo MS+ integration enhances high-throughput mass spectrometry

SCIEX expands compatibility with the ZenoTOF 8600 system to deliver greater sensitivity and automation capabilities
Manufacturing

IMA strengthens aseptic and containment capabilities with ProSys acquisition

The deal expands IMA’s isolator and sampling technology portfolio for the global biopharmaceutical market
Subscribe now